DERMATOLOGY

Open Journal



Case Report

Palmoplantar Psoriasis Successfully Treated with Raw Natural Honey: A Case Report

Lowlwa Al Meslamani, MD¹; Badriya Al Lenjawi, PhD²; Shawkia Al Majid, MD¹; Hashim Mohamed, MD³

*Corresponding author

Hashim Mohamed, MD

Associate Professor, Senior Consultant Family Medicine, Weill Cornell Medical College-Qatar, Doha, Qatar; E-mail: fmcc2000@gmail.com

Article information

Received: November 6th, 2018; Revised: November 28th, 2018; Accepted: December 11th, 2018; Published: January 4th, 2019;

Cite this article

Al Meslamani L, Al Lenjawi B, Al Majid S, Mohamed H. Palmoplantar psoriasis successfully treated with raw natural honey: A case report. Dermatol Open J. 2019; 4(1): 1-6. doi: 10.17140/DRMTOJ-4-133

ABSTRACT

Palmoplantar psoriasis is a disabling condition linked to significant reduction in quality-of-life. It is manifested by the development of hyperkeratosis and/or recurrent batches of sterile pustules with associated erythema, scaling, and fissuring with symmetrical distribution on the palm and soles. Many modalities of treatment exist including systemic therapies such as psoralen-UVA (PUVA), retinoids, corticosteroids cyclosporine and methotrexate. Many of these systemic agents have un wanted and severe side effects besides their high cost. Furthermore, new agents such as TNF-alfa blockers have been reported to cause paradoxical induction of pustular psoriasis following their use or withdrawal. As a result safe, topical and effective alternatives are highly needed in treating this chronic condition. We describe the clinical characteristics and evolution of a 68-years-old female with palmoplantar psoriasis who was treated successfully with topical raw honey. This report provides preliminary evidence to support the use of topical raw honey under occlusive dressing in the management of palmoplantar psoriasis.

Keywords

Palmoplantar psoriasis; Raw natural honey; Inflammation.

INTRODUCTION |

 ${f P}$ almoplantar psoriasis is a disabling condition that is difficult to treat and is present in up to 40% of patients with plaque psoriasis. It is a disabling condition that can manifest in a hyperkeratotic plaque-type, pustular form or combination. In comparison with plaque psoriasis on other areas of the body, palmoplantar psoriasis leads to a disproportionately greater impairment of health-related quality of life (HRQoL).² Psoriasis is a multifactorial condition influenced by numerous factors in its presence and severity, such as stress, exercise, alcohol, obesity, etc. Patients with palmoplantar psoriasis have difficulty walking, suffer a significant amount of pain in the palms and soles which may lead to an inability to work.²⁻⁴ Palmoplantar psoriasis typically represents a difficult to treat variety of psoriasis and unlike plaque-type psoriasis, pustular psoriasis is characterized by homozygous or compound heterozygous interleukin-36 (IL36RN) gene mutations leading to aberrations in IL-36R antagonist function.⁵ The thickened horny layer of palmar and plantar⁶ epidermis partially causes low bioavailability of classic topical anti-psoriatic drugs, hence the unsatisfactory results after prolonged usage. Systemic treatment on the

other hand may include psoralen-UVA (PUVA), systemic retinoids and a combination of both, ^{7,8} but they often fail to give convincing results. ⁹ Tumor necrosis factor (TNF) antagonists are successfully being used in the treatment of psoriasis. However, unexpected side effect of TNF antagonists include the new onset or worsening of psoriatic skin lesions, ¹⁰⁻¹⁵ eczematous eruptions, bacterial infections, herpes simplex, cutaneous lymphomas, lichenoid eruptions, erythema multiforme, acute generalized exanthematous pustulosis and lupus erythematosus pustulosis. Acitretin, cyclosporins lead to quick remissions but recurrence rate limits their wide application. Here we present a case report in which a patient with palmoplantar pustular psoriasis showed complete healing with raw natural honey.

CASE REPORT

An otherwise healthy female subject, 68-years-old, presented to Umgwailinah Health Center, Doha, Qatar, with pustule palmar psoriasis (Figure 1), on her feet, showing numerous small flat pustules (2-3 mm in diameter), yellowish in color, on an erythematous basis

© Copyright 2019 by Mohamed H. This is an open-access article distributed under Creative Commons Attribution 4.0 International License (CC BY 4.0), which allows to copy, redistribute, remix, transform, and reproduce in any medium or format, even commercially, provided the original work is properly cited.

Primary Care Corporation, Doha, Qatar

²Hamad Medical Corporation, Doha, Qatar

³Senior Consultant Family Medicine, Weill Cornell Medical College-Qatar, Doha, Qatar







The patient was complaining of continuous pain and burning sensation. She reported the appearance of her feet lesions about three months prior to presentation, and explained the emergence of new pustules in few hours, while older lesions were forming a yellowish crust which were falling spontaneously after few days. The patient does not smoke, had no family history of psoriasis or other skin diseases, was not on any medications and reported no contact with any topical irritants. Further clinical evaluation was negative for bone or joint pain suggestive of concomitant arthritis or Synovitis-Acne-Pustulosis-Hyperostosis-Osteitis (SAPHO) syndrome. Additionally, the patient did not report any symptoms suggestive of thyroid disease or gluten sensitivity (eg, diarrhea, flatulence, abdominal pain, steatorrhea). Family history was negative for thyroid and coeliac disease. During the clinical examination, no other lesions were observed in any other part of the body including the nails. A rheumatologic assessment showed no clinical joint involvement and blood investigations for inflammation and infections was negative. The patient had visited a dermatologist prior to presenting to our health center. He carried out clinical examination, took swabs and blood cultures for infections which revealed sterile pustules and negative serology for infections. Similarly, mycological and bacteriological test was carried and found to be negative. This was followed by a punch biopsy on which revealed subcorneal unilocular pustulosis filled with neutrophils and eosinophils in the upper dermis and mixed perivascular and diffuse infiltrate in the dermis (neutrophils, eosinophils, lymphocytes

and mast cells). Epidermal changes revealed (loss of granular layer, parakeratosis and psoriasiform epidermal hyperplasia).

On examination, the patient had bilateral well-demarcated erythema, hyperkeratosis, desquamation and multiple pustules on the instep, medial border and at the insertion of the Achilles tendon (Figure (1)). It involved at least 50 percent of the plantar surface significantly limiting her daily activities with no additional body involvement. The patient was instructed to apply raw honey directly on the lesions and cover it with Adaptic (glycerin based dressing) to prevent the absorption of natural honey away from the lesions and into the secondary cotton gauze bandage. The dressing was changed on a daily basis, and the patient was educated about a transient stinging sensation at the site of application due to the acidic nature of honey. After eight weeks the clinical picture of the right foot was substantially improved, showing a reduction of inflammation, desquamation, and complete disappearance of pustules (Figure (2a)). On the left foot similar finding were achieved with total resolution of the inflammation, erythema, desquamation and pustules (Figure (2b)).





DISCUSSION AND CONCLUSION

Despite the wide range of therapeutic options, treatment of a patient with palmoplantar psoriasis can be challenging. Although systemic therapies often show initial efficacy, none the less relapse and



unwanted side effects along with resistance by some patients to any kind of therapy leads to frustration and disappointment by both patients and healthcare providers. According to a systematic review by Li l et al16 current topical treatments including laser therapy, tazarotene ointment and methotrexate gel apart from phototherapy do not have sufficient evidence to justify their use. None theless, phototherapy needs to be administered over a long treatment period, around 21.9 months before noticeable improvements can be seen,¹⁷ it also causes erythema, irritation and burning.^{16,17,18} Topical methotrexate has been advocated as an adequate alternative to systemic side effects with less adverse effects. 19 However, a small prospective, open label study involving fourteen patients showed variable results by Kumar et al.20 Similar to PUVA various side effects have been reported with topical methotrexate including redness, burning sensation, purpura and blisters at the site of application. 21-23 Tar topical ointment had been studied in the treatment of Palmoplantar Psoriasis (PPP) by Kumar et al, however only 50% of patients reported improvements in their symptoms^{24,25} along with various side effects including pruritus, itchiness, folliculitis, staining, irritant contact dermatitis and redness.²⁶ Similar disappointing results had been obtained with topical retinoids where only 52.9% of patients with PPP achieved complete resolution maxacalcitol ointment where only 17% of test subjects reported marked improvements.^{27,28} Although topical corticosteroids are an integral part of the therapeutic options available to treat psoriatic lesions, numerous and common cutaneous side effects are undesirable and lead to dissatisfaction among patients and health care practitioners alike. The most common side effect being striae rubrae distensae, skin trophy and perturbed cicatrization. Steroid acne, hypertrichosis perioral dermatitis, telangiectasia, erythema, rubeosis steroidica and hyperpigmentation may also occur.²⁹ Furthermore, topical steroids may exacerbate cutaneous bacterial or fungal infections.³⁰

Maintaining corticosteroids efficacy and at the same time abolishing side effects represents a formidable challenge to clinicians and researchers alike. The use of raw of natural honey in the management of various cutaneous lesions including, seborrheic dermatitis,31 knee psoriasis,32 thermal burns,33 second degree burns complicated by dermatitis34 and chronic diabetic foot ulcers³⁵⁻⁴¹ provides a promising alternative remedy for PPP. The patient did apply various over the counter creams including aqueous cream, petroleum based jelly and glycerin prior to her presentation to us but was disappointed with the results. In our case, we specifically used a glycerin based barrier dressing to maximize contact of raw honey with the skin by preventing the absorption of honey onto the secondary dressing (cotton gauze). Application of honey provides a thick film that provides continuous supply of water and at the same time hinders water evaporation from the skin. Therefore, the water content of raw honey increases hydration in the stratum corneum and consequently leads to reduction in scaling and erythema and pruritus associated with psoriasis.

The anti-inflammatory effects of honey have been observed in animal models as well in clinical settings.⁴² Some compounds like prostaglandins and nitric oxide are major players in the process of inflammation. Honey is known to increase nitric oxide end products and decrease the prostaglandin levels. The efficacy

of natural honey in wound care has been attributed to its antiinflammatory activity. Important constituents in honey thought to be responsible for its anti-inflammatory activity include flavonoids, specific polyphenols, phenethyl ester, and caffeic acid. Honey exerts its anti- inflammatory activity by suppressing the production and proliferation of inflammatory cells at the site of inflammation (wound), thereby preventing the prolonged inflammatory response, and at the same time enhances proinflammatory cytokine production, thereby helping normal healing to occur. Wound healing involves a remodeling process of the inflicted tissue, consisting of a systematic cascade of events comprising various interactions that are regulated by growth factors, cytokines, and proteases. An important marker of inflammation is the transcription factor nuclear factor-kappa beta (NF-KB). It stimulates proinflammatory activity which in turn contributes to an amplified inflammatory response, and stimulates genes encoding for proinflammatory cytokines tumor necrosis factor-α (TNF-α), interleukin (IL)-6, IL-8. As a result of enhanced production of proinflammatory cytokines, nitric oxide production is stimulated, an essential mediator of inflammation. Flavonoid in honey suppresses the production of nitric oxide and NF-KB activation.⁴³ Cost-effective, efficacious, topical and tolerable remedies are needed to treat this long-term disease due to the low quality of life patients with psoriasis have. Nonetheless rigorous clinical trials have to be conducted to validate the efficacy of natural honey with regards of type of honey, concentration of flavonoids and optimal duration of therapy.

In a recent Cochrane systematic review the authors concluded "Honey appears to heal partial thickness burns more quickly than conventional treatment (which included, soframycin-impregnated gauze, paraffin gauze polyurethane film, sterile linen and leaving the burns exposed) and infected post-operative wounds more quickly than antiseptics and gauze".44 Another systematic review assessing the healing effects of honey dressings compared to silver dressings for acute or chronic wounds demonstrated the unequivocal result that honey had an even more positive effect than silver on wound healing.⁴⁵ The rational of using honey is that it not only provides moisture but rather exhibits anti-inflammatory actions thereby helping in the management of psoriasis. Honey anti-inflammatory activities is partially due to the presence of at least 11 phenolic compounds such as kaempferol and caffeic acid which leads to a decrease in the myeloperoxidase activity in 75±3%, which suggests a lower leucocyte infiltration that was confirmed by histological analysis. This extract also provided a reduction of 55±14% in the production of reactive oxygen species.46 Furthermore, honey flavonoid significantly inhibits the release of pro-inflammatory cytokines such as TNF-α, IL-1β and the production of reactive oxygen intermediates (ROS).⁴⁷

The anti-inflammatory effects of honey can be summarized by several mechanisms of action: (a) inhibition of leukocyte infiltration⁴⁸ (b) inhibition of matrix metal-loproteinase-9 (MMP-9) production in keratinocytes, inhibition of ROS formation⁴⁹ (c) inhibition of cyclooxygenase-2 (COX-2) and iNOS expression.⁵⁰

Phenolic compounds (including flavonoids) are demonstrated to exert the primarily anti-inflammatory effects of honey.⁵¹



Chrysin, a flavonoid discovered in honey, has been demonstrated to have a powerful anti-inflammatory action.⁵² It suppresses lipopolysaccharide-induced COX-2 expression through the inhibition of nuclear factor for IL-6 Deoxyribonucleic acid (DNA)-binding activity⁵³ and inhibits the release of NO and pro-inflammatory cytokines such as TNF-α and IL-1β. Furthermore, Majtan et al⁵⁴ discovered two other flavonoids in aqueous extract of honey, namely kaempferol, and apigenin which suppresses the activity of TNF-α-induced Multiple Medical Problems (MMP)-9 expression in HaCaT. Their findings are in line with Palmieri et al where apigenin inhibited TNF-α-induced MMP-9 expression *via* modulating Akt signaling in endothelial cells.⁵⁵

Honey has been used here as an alternative therapy due to the preference of the patient (patient centered care) who refused flatly the main stream medical approach, so the wish of the patient was respected and as a result topical honey was used. The idea of having natural honey as a first line agent is not the intent of this case report but rather it's an eye opener for the scientific committee to think of utilizing a safe and cost-effective approach which can only be advocated after a rigorous multicenter randomized controlled clinical trial.

CONSENT |-

The authors have received written informed consent from the patient.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

REFERENCES |

- 1. Bolognia J, Jorizzo JL, Rapini RP. *Dermatology*. 2nd Eds. Maryland Heights, Missouri, US: Mosby Elsevier. 2008.
- 2. Pettey AA, Balkrishnan R, Rapp SR, Fleischer AB, Feldman SR. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: Implications for clinical practice. *J Am Acad Dermatol.* 2003; 49: 271-275. doi: 10.1067/S0190-9622(03)01479-8
- 3. Lee E, Zarei M, LaSenna C, Villada G, Romanelli P. Psoriasis targeted therapy: Characterization of interleukin 17A expression in subtypes of psoriasis. *J Drugs Dermatol.* 2015; 14: 1133-1136.
- 4. Kumar B, Saraswat A, Kaur I. Palmoplantar lesions in psoriasis: A study of 3065 patients. *Acta Derm Venereol.* 2002; 82: 192-195. doi: 10.1080/00015550260132488
- 5. Jacobi A, Mayer A, Augustin M. Keratolytics and emollients and their role in the therapy of psoriasis: A systematic review. *Dermatol Ther (Heidelb)*. 2015; 5: 1-18. doi: 10.1007/s13555-015-0068-3
- 6. Adişen E, Tekin O, Gülekon A, Gürer MA. A retrospective

- analysis of treatment responses of palmoplantar psoriasis in 114 patients. *J Eur Acad Dermatol Venereol.* 2009; 23: 814-819. doi: 10.1111/j.1468-3083.2009.03197.x
- 7. Khandpur S, Sharma VK. Comparison of clobetasol propionate cream plus coal tar *vs.* topical psoralen and solar ultraviolet a therapy in palmoplantar psoriasis. *Clin Exp Dermatol.* 2011; 36: 613-616. doi: 10.1111/j.1365-2230.2011.04061.x
- 8. Raposo I, Torres T. Palmoplantar psoriasis and palmoplantar pustulosis: Current treatment and future prospects. *Am J Clin Dermatol.* 2016; 17: 349-358. doi: 10.1007/s40257-016-0191-7
- 9. Mehta BH, Amladi ST. Evaluation of topical 0.1% tazarotene cream in the treatment of palmoplantar psoriasis: An observer-blinded randomized controlled study. *Indian J Dermatol.* 2011; 56: 40-43. doi: 10.4103/0019-5154.77550
- 10. Lozinski A, Barzilai A, Pavlotsky F. Broad-band UVB *versus* paint PUVA for palmoplantar psoriasis treatment. *J Dermatolog Treat*. 2016; 27: 221-223. doi: 10.3109/09546634.2015.1093588
- 11. Hawk JL, Grice PL. The efficacy of localized PUVA therapy for chronic hand and foot dermatoses. *Clin Exp Dermatol.* 1994; 19: 479-482. doi: 10.1111/j.1365-2230.1994.tb01251.x
- 12. Carrascosa JM, Plana A, Ferrándiz C. Effectiveness and safety of psoralen-UVA (PUVA) topical therapy in palmoplantar psoriasis: A report on 48 patients. *Actas Dermosifiliogr.* 2013; 104: 418-425. doi: 10.1016/j.adengl.2013.04.005
- 13. Abel EA, Goldberg LH, Farber EM. Treatment of palmoplantar psoriasis with topical methoxsalen plus long-wave ultraviolet light. *Arch Dermatol.* 1980; 116: 1257-1261. doi: 10.1001/archderm.116.11.1257
- 14. Neumann NJ, Mahnke N, Korpusik D, Stege H, Ruzicka T. Treatment of palmoplantar psoriasis with monochromatic excimer light (308-nm) *versus* cream PUVA. *Acta Derm Venereol.* 2006; 86: 22-24. doi: 10.2340/00015555-0002
- 15. Coleman WR, Lowe NJ, David M, Halder RM. Palmoplantar psoriasis: Experience with 8-methoxypsoralen soaks plus ultraviolet A with the use of a high-output metal halide device. *J Am Acad Dermatol.* 1989; 20: 1078-1082. doi: 10.1016/S0190-9622(89)70136-5
- 16. Schiener R, Gottlöber P, Müller B, et al. PUVA-gel vs. PUVA-bath therapy for severe recalcitrant palmoplantar dermatoses. *Photodermatol Photoimmunol Photomed.* 2005; 21: 62-67. doi: 10.1111/j.1600-0781.2005.00134.x
- 17. Gupta S, Singh K, Lalit M. Comparative therapeutic evaluation of different topicals and narrow band ultraviolet B therapy combined with systemic methotrexate in the treatment of palmoplantar psoriasis. *Indian J Dermatol.* 2011; 56: 165-170. doi: 10.4103/0019-



5154.80410

- 18. Goldberg DJ, Chwalek J, Hussain M. 308-nm Excimer laser treatment of palmoplantar psoriasis. *J Cosmet Laser Ther.* 2011; 13: 47-49. doi: 10.3109/14764172.2011.564769
- 19. Furuhashi T, Torii K, Kato H, Nishida E, Saito C, Morita A. Efficacy of excimer light therapy (308 nm) for palmoplantar pustulosis with the induction of circulating regulatory T cells. *Exp Dermatol.* 2011; 20: 768-770. doi: 10.1111/j.1600-0625.2011.01316.x
- 20. Nisticò SP, Saraceno R, Chiricozzi A, Giunta A, Di Stefani A, Zerbinati N. UVA-1 laser in the treatment of palmoplantar pustular psoriasis. *Photomed Laser Surg.* 2013; 31: 434-438. doi: 10.1089/pho.2013.3545
- 21. Kim YC, Lee ES, Chung PS, Rhee CK. Recalcitrant palmoplantar pustular psoriasis successfully treated with topical 5-aminolae-vulinic acid photodynamic therapy. *Clin Exp Dermatol.* 2005; 30: 723-724. doi: 10.1111/j.1365-2230.2005.01905.x
- 22. Yamamoto T. Extra-palmoplantar lesions associated with palmoplantar pustulosis. *J Eur Acad Dermatol Venereol.* 2009; 23: 1227-1232. doi: 10.1111/j.1468-3083.2009.03296.x
- 23. Kumar B, Sandhu K, Kaur I. Topical 0.25% methotrexate gel in a hydrogel base for palmoplantar psoriasis. *J Dermatol.* 2004; 31: 798-801. doi: 10.1111/j.1346-8138.2004.tb00602.x
- 24. Ravi Kumar BC, Kaur I, Kumar B. Topical methotrexate therapy in palmoplantar psoriasis. *Indian J Dermatol Venereol Leprol.* 1999; 65: 270-272.
- 25. Kumar U, Kaur I, Dogra S, De D, Kumar B. Topical tazarotene vs. coal tar in stable plaque psoriasis. *Clin Exp Dermatol.* 2010; 35: 482-486. doi: 10.1111/j.1365-2230.2009.03610.x
- 26. Umezawa Y, Nakagawa H, Tamaki K. Phase III clinical study of maxacalcitol ointment in patients with palmoplantar pustulosis: A randomized, double-blind, placebo-controlled trial. *J Dermatol.* 2016; 43: 288-293. doi: 10.1111/1346-8138.13064
- 27. Duweb GA, Abuzariba O, Rahim M, al-Taweel M, al-Alem S, Abdulla SA. Occlusive *versus* nonocclusive calcipotriol ointment treatment for palmoplantar psoriasis. *Int J Tissue React.* 2001; 23: 59-62.
- 28. Fluhr JW, Cavallotti C, Berardesca E. Emollients, moisturizers, and keratolytic agents in psoriasis. *Clin Dermatol.* 2008; 26: 380-386. doi: 10.1016/j.clindermatol.2008.01.015
- 29. Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. *Pharmacology and Therapeutics*. 2002; 96(1): 23-43. doi.org/10.1016/S0163-7258(02)00297-8

- 30. Arenas R, Moreno-Coutiño G, Vera L, Welsh O. Tinea incognito. *Clinics in Dermatology*. 2010; 28(2): 137-139. doi: 10.1016/j. clindermatol.2009.12.011
- 31. Al Sayed Mohammed H, Al-Lenjawi B, Mendoza D. Seborrheic dermatitis treatment with natural honey . *Wounds International.* 2018; 9: 36-38.
- 32. Kherallah B, Gouda Z, Mohamed H. Efficacy of natural honey *Versus* fluticasone propionate in mild psoriasis: A case study. *Wounds.* 2017; 29: E78-E83.
- 33. Al-Lenjawi B, Mohamed H, Abu Salma M, Abo Gouda Z. Natural honey in the management of thermal burn of the foot in a type 2 diabetic patient: A case report. *Dermatol Open J.* 2016; 1: 14-18. doi: 10.17140/DRMTOJ1-105
- 34. Mohamed H, Abo Salma M, Al-Lenjawi B, et al. The efficacy of natural honey in the management of second degree burn complicated by acute dermatitis in a diabetic patient. *J Diabetes Metab.* 2014; 5: doi: 10.4172/2155-6156.1000373
- 35. Mohamed H. Successful healing of diabetic foot ulcers and various etiology ulcers with natural honey: An alternative paradigm in wound healing. *J Diab Rel Dis.* 2016; 1(1): 107.
- 36. Mohamed H, Abu Salma M, Al-Lenjawi B, et al. The efficacy and safety of natural honey on the healing of foot ulcers: A case series. *Wounds*. 2015; 27(4): 103-114.
- 37. Mohamed H. Natural honey as an adjunctive alternative in the management of diabetic foot ulcers. *J Diabetes Metab* . 2012; 20(4): 212-216. doi: 10.4172/2155-6156.S1.028
- 38. Mohamed H, Al-Lenjawi B, Abu Salma M, Abdi S. Honey based therapy for the management of a recalcitrant diabetic foot ulcer. *J Tissue Viability*. 2014; 23(1): 29-33. doi: 10.1016/j.jtv.2013.06.001
- 39. Mohamed H, Salma MA, Al-Lenjawi B, et al. Enhancing primary healing post ray amputation in a diabetic patient: Efficacy of natural honey. *Journal of Diabetic Foot Complications*. 2014; 6(1): 13-18.
- 40. Al-Lenjawi B, Mohamed H, Al-Ali A, Kherallah B. Are all wound products created equally? The re-emergence of natural honey. *The Journal of Diabetic Foot Complications*. 2015; 7(2): 26-41.
- 41. Tonks AJ, Cooper RA, Jones KP, Blair S, Parton J, Tonks A. Honey stimulates inflammatory cytokine production from monocytes. *Cytokine*. 2003; 21(5): 242–347. doi: 10.1016/S1043-4666(03)00092-9
- 42. Tomblin V, Ferguson LR, Han DY, Murray P, Schlothauer R. Potential pathway of anti-inflammatory effect by New Zealand honeys. *Int J Gen Med.* 2014; 7: 149-158. doi: 10.2147/IJGM.



S45839

- 43. Jull AB, Cullum N, Dumville JC, Westby MJ, Deshpande S, Walker N. Honey as a topical treatment for wounds. *Cochrane Database Syst Rev.* 2015, (3): CD005083. doi: 10.1002/14651858. CD005083.pub4
- 44. Lindberg T, Andersson O, Palm M, Fagerström C. A systematic review and meta-analysis of dressings used for wound healing: The efficiency of honey compared to silver on burns. *Contemp Nurse*. 2015; 51: 121-134. doi: 10.1080/10376178.2016.1171727
- 45. Borsato DM, Prudente AS, Döll-Boscardin PM, et al. Topical anti-inflammatory activity of a monofloral honey of Mimosa scabrella provided by Melipona marginata during winter in southern Brazil. *J Med Food.* 2014; 17(7): 817-825. doi: 10.1089/jmf.2013.0024
- 46. Candiracci M, Piatti E, Dominguez-Barragán M, et al. Anti-inflammatory activity of a honey flavonoid extract on lipopolysac-charide-activated N13 microglial cells. *J Agric Food Chem.* 2012; 60: 12304-12311. doi: 10.1021/jf302468h
- 47. Leong AG, Herst PM, Harper JL. Indigenous New Zea-land honeys exhibit multiple anti-inflammatory activities. *Innate Immun*. 2012; 18: 459-466. doi: 10.1177/1753425911422263
- 48. Zare A, Ahmadi M, Hedayat A. Study on anti-inflam-matory effect of subcutaneous honey bee venom injection and dermal application of cream containing honey bee venom in adjuvant-induced arthritic rats. *Arch Razi Inst.* 2007; 62: 223–227. doi: 10.22092/ARI.2007.103758
- 49. Hussein SZ, Mohd Yusoff K, Makpol S, Mohd Yusof YA.

- Gelam honey inhibits the production of proinflammatory, mediators NO, PGE(2), TNF-α, and IL-6 in carrageenan-induced acute paw edema in rats. *Evid Based Compl Alt Med.* 2012; 2012: 1-12. doi: 10.1155/2012/109636
- 50. Ahmad A, Khan RA, Mesaik MA. Anti-inflammatory effect of natural honey on bovine thrombin-induced oxidative burst in phagocytes. *Phytother Res.* 2009; 23: 801-808. doi: 10.1002/ptr.2648
- 51. Kassim M, Achoui M, Mustafa MR, Mohd MA, Yusoff KM. Ellagic acid, phenolic acids, and flavonoids in Malaysian honey extracts demonstrate in vitro anti–inflammatory activity. *Nutr Res.* 2010; 30: 650-659. doi: 10.1016/j.nutres.2010.08.008
- 52. Yang H, Liu Q, Ahn JH, et al. Luteolin down regulates IL-1b-in-duced MMP-9 and -3 expressions in osteoblasts *via* inhibi-tion of ERK signaling pathway. *J Enzyme Inhib Med Chem.* 2012; 27: 261-226.
- 53. Majtan J, Bohova J, Garcia-Villalba R, et al. Fir hon-eydew honey flavonoids inhibit TNF-a-induced MMP-9 expression in human keratinocytes: A new action of honey in wound healing. *Arch Dermatol Res.* 2013; 305: 619-627. doi: 10.1007/s00403-013-1385-y
- 54. Woo KJ, Jeong YJ, Inoue H, Park JW, Kwon TK. Chrysin suppresses lipopolysaccharide-induced cycloooxy-genase-2 expression through the inhibition of nuclear fac-tor for IL-6 (NF-IL-6) DNA-binding activity. *FEBS Lett.* 2005; 579: 705-711. doi: 10.1016/j.feb-slet.2004.12.048
- 55. Palmieri D, Perego P, Palombo D. Apigenin inhibits the TNFα-induced expression of eNOS and MMP-9 *via* modulating Akt signalling through oestrogen receptor engagement. *Mol Cell Biochem.* 2012; 371(1-2): 129-136. doi: 10.1007/s11010-012-1429-1